PHILADELPHIA – When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers, according to results published in Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, explained lead author Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Zhu added that colorectal cancer screening is particularly underutilized by individuals experiencing socioeconomic disadvantages, racial and ethnic minorities, and certain age groups.
22 APRIL 2021
Many women who are genetically susceptible to breast cancer have no idea they can take preventative medication to reduce their risk of developing the disease, according to new research from Australia.
When taken daily for five years, estrogen receptor modulators, like tamoxifen, and aromatase inhibitors, like anastrozole, can cut the risk of breast cancer from one third to one half in high-risk patients, and these benefits can continue for many years after the medication is stopped.
Given such promising results, current national guidelines in multiple countries recommend preventative therapies are offered to patients at high risk of developing breast cancer, and yet today, an astonishing number of patients and clinicians seem to have no awareness that these options exist.
E-Mail
Bottom Line: When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often recommended by health care providers.
Journal in Which the Study was Published:
Cancer Prevention Research, a journal of the American Association for Cancer Research
Author: Xuan Zhu, PhD, senior health services analyst at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
Background: Although colorectal cancer is the second most frequent cause of cancer-related death in the United States, about one-third of eligible American adults have never completed a colorectal cancer screening test, explained lead author Zhu. Zhu added that colorectal cancer screening is particularly underutilized by individuals experiencing socioeconomic disadvantages, racial and ethnic minorities, and certain age groups.
Study suggests common drug could be used to prevent certain skin cancers ANI | Updated: Apr 14, 2021 19:09 IST
Washington [US], April 14 (ANI): A new research has suggested that an oral drug currently used in the clinical setting to treat neuromuscular diseases could also help prevent a common form of skincancer caused by damage from ultraviolet-B radiation from the sun.
The findings of the study were published in the journal Cancer Prevention Research .
The study was led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).
While this data was gathered from preclinical studies, senior author Sujit Basu, MD, PhD, says preliminary results in animal models are very promising and worthy of immediate further investigation through phase I human studies.
Routine Drug may be Used to Prevent Few Skin Cancers by Angela Mohan on April 14, 2021 at 12:42 PM
Skin cancer could be treated by an oral drug currently used in the clinical setting to treat neuromuscular diseases, as per the data published by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
While this data was gathered from preclinical studies, senior author Sujit Basu, MD, PhD, says preliminary results in animal models are very promising and worthy of immediate further investigation through phase I human studies.